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ABSTRACT
Objectives The clinical and public health relevance of 
widespread case finding by testing for asymptomatic 
chlamydia infections is under debate. We wanted to 
explore future directions for chlamydia control and 
generate insights that might guide for evidence- based 
strategies. In particular, we wanted to know the extent 
to which we should pursue testing for asymptomatic 
infections at both genital and extragenital sites.
Methods We synthesised findings from published 
literature and from discussions among national and 
international chlamydia experts during an invitational 
workshop. We described changing perceptions in 
chlamydia control to inform the development of 
recommendations for future avenues for chlamydia 
control in the Netherlands.
Results Despite implementing a range of interventions 
to control chlamydia, there is no practice- based evidence 
that population prevalence can be reduced by screening 
programmes or widespread opportunistic testing. There 
is limited evidence about the beneficial effect of testing 
on pelvic inflammatory disease prevention. The risk of 
tubal factor infertility resulting from chlamydia infection 
is low and evidence on the preventable fraction remains 
uncertain. Overdiagnosis and overtreatment with 
antibiotics for self- limiting and non- viable infections 
have contributed to antimicrobial resistance in other 
pathogens and may affect oral, anal and genital 
microbiota. These changing insights could affect the 
outcome of previous cost–effectiveness analysis.
Conclusion The balance between benefits and harms 
of widespread testing to detect asymptomatic chlamydia 
infections is changing. The opinion of our expert group 
deviates from the existing paradigm of ’test and treat’ 
and suggests that future strategies should reduce, 
rather than expand, the role of widespread testing for 
asymptomatic chlamydia infections.
INTRODUCTION
Chlamydia control strategies are based on the 
prevailing infectious disease paradigm that control 
of STIs is achieved by reducing the reproduction 
number (R0) of Chlamydia trachomatis, the bacte-
rium that causes chlamydia infection. The formula 
R0=βcD shows that the reproduction number can 
be reduced by preventing acquisition (reducing 
transmission efficiency β), limiting the partner 
change rate (c) and/or by reducing the duration 
of infectiousness (D). Behavioural interventions, 
such as increasing correct and consistent condom 
use, are primary prevention interventions to reduce 
transmission. Testing and treatment are secondary 
prevention interventions that aim to reduce the 
duration of infectiousness (D). As most chlamydia 
infections are asymptomatic, finding and treating 
these infections start with testing and case finding.
Early diagnosis and treatment should prevent 
onward transmission and individual adverse health 
outcomes. For HIV infection, this ‘test and treat’ 
strategy has proven to be a very effective and 
successful public health intervention. In the Neth-
erlands, the number of annual new HIV diagnoses 
reduced by 72% in the last 10 years.1 However, no 
such trend exists for chlamydia, despite widespread 
opportunistic testing for asymptomatic infections 
(figure 1).2
The Dutch National Action Plan on STI, HIV 
and Sexual Health 2017–2022 recommended an 
update of the strategies to prevent the burden of 
disease caused by infections with C. trachomatis 
(‘chlamydia’).3
In November 2019, an invitational workshop 
brought together a range of national and interna-
tional chlamydia experts to explore future avenues 
for chlamydia control in the Netherlands (see online 
supplemental file 1). In particular, we wanted to 
know the extent to which we should pursue testing 
for asymptomatic infections at both genital and 
extragenital sites. In this paper, we describe our 
problem analysis and the main outcome of the 
workshop.
METHODS
To capture recommendations about how imper-
fect evidence might be translated into a roadmap 
for the near future in the Netherlands, we chose to 
draw on expert opinion collated during a meeting 
that included the authors of this paper. The expert 
meeting was preceded by a narrative review of 
reviews and relevant articles (JvB), synthesised and 
presented during the 2019 International Union 
Against STI Europe conference4 and presented at 
the start of the expert meeting. We also used as 
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background the external review evidence pack of the English 
National Chlamydia Screening Programme External Peer 
Review.5 We asked meeting participants if their perspectives 
on chlamydia control had changed over the preceding 10 years 
and discussed the evidence for these changes. We elaborated on 
views and interpretation of available evidence about organised 
screening programmes (referred to as screening) and on oppor-
tunistic testing of asymptomatic persons in healthcare settings 
(referred to as routine testing) and discussed the impact of this 
widespread testing, including out- of- clinic testing and internet 
testing for chlamydia infections.
Our debates covered heterosexual persons, men who have sex 
with men (MSM) and pregnant women (online supplemental 
file 2). The problem analysis and the consensus viewpoint that 
evolved from this expert meeting showed a shift from the existing 
‘test and treat’ paradigm in chlamydia control and suggests that 
future strategies should reduce, rather than expand, the role of 
widespread testing for asymptomatic chlamydia infections.
Problem analysis
Early detection and treatment aim to limit onward spread and 
prevent reproductive health sequelae in women. New devel-
opments in point- of- care tests, mobile health, home sampling 
and internet testing offer increasing opportunities to implement 
widespread testing to detect asymptomatic chlamydia infec-
tions, including extragenital infections.6–8 However, the clin-
ical and public health relevance of active case finding by testing 
for asymptomatic infections is under debate.9–11 The balance 
between benefits and harms of testing for asymptomatic infec-
tions might be changing for three reasons: (1) empirical evidence 
does not support the claim that enhanced testing of asympto-
matics reduces the incidence and prevalence of chlamydia infec-
tion; (2) the risk of long- term complications attributable to a 
chlamydia infection in particular the risk of tubal factor infer-
tility (TFI) is considered low and there is uncertainty about the 
fraction that can be prevented by routine testing; (3) there is 
more acknowledgement of the harms related to overdiagnosis 
and overtreatment, including the potential for antimicrobial 
resistance in other pathogens.
Lack of evidence for prevalence reduction
In 2018, 26 European Union/European Economic Area member 
states reported 406 406 confirmed cases of chlamydia infection. 
The overall notification rate of confirmed cases between 2009 and 
2018 remained rather stable in countries reporting consistently, 
including countries recommending widespread testing like the 
UK and the Scandinavian countries.12 Surveillance data however 
relate to the amount of testing in a country and who is being 
tested. They do not reflect population prevalence: ecological 
associations do not provide evidence of effectiveness of interven-
tions and may even lead to ‘ecological fallacies’.13 Research from 
pragmatic randomised controlled trials and observational studies 
of chlamydia prevalence has accumulated in the last decade. That 
evidence suggests that real- life screening programmes or wide-
spread opportunistic testing is unlikely to reduce prevalence. The 
chlamydia screening implementation programme in three regions 
in the Netherlands concluded that, at the achieved levels of uptake, 
there was no statistical evidence of an impact on chlamydia posi-
tivity rates or estimated population prevalence after 3 years of a 
regular postal invitation to all persons aged 16–29 years to take a 
sample at home and mail it for a screening test for C. trachomatis. 
As a result, the Dutch government decided not to implement a 
national roll- out of register- based chlamydia screening.9 10 The 
National Chlamydia Screening Program in England has driven 
large increases in chlamydia testing since 2003, testing in the 
last decade more than 1 million young people aged 15–24 years, 
including up to 30% of all young women.14 Although previous 
modelling studies estimated that these levels of uptake should be 
sufficient to reduce population prevalence, two population- based 
surveys, done as part of the British National Surveys of Sexual 
Attitudes and Lifestyles, found that the prevalence estimates were 
compatible with no decrease in chlamydia prevalence between 
2000 and 2011.15 The National Chlamydia Screening Program 
in England conducted an internal and external review and is now 
reframing its priorities.5 In Australia, the Australian Chlamydia 
Control Effectiveness Pilot, a cluster randomised controlled trial 
from 2010 to 2014, concluded that a sustained and relevant 
uptake of widespread testing was not feasible and that sizeable 
reductions in chlamydia prevalence are unlikely to be achieved.16
Figure 1 Total number of tests and positivity rate of chlamydia by gender and type of sexual contact, 2010–2019 Sexual Health Centres in the 
Netherlands.2 MSM, men who have sex with men.
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Low rates of severe long-term complications
Potential short- term and long- term complications for women 
are pelvic inflammatory disease (PID) and compromised fertility 
(TFI and risk of ectopic pregnancy) and chronic pelvic pain. 
For PID, it is difficult to obtain reliable data because most diag-
noses are based on clinical signs and symptoms only, there is no 
accepted gold standard for diagnosis and the concept of ‘silent’ 
PID contributes to diagnostic uncertainty. A multiparameter 
evidence synthesis, which uses statistical modelling informed by 
empirical data, estimated the population attributable fraction 
of chlamydia infection in PID to be around 20%–30%.17 There 
is limited, low to moderate quality evidence from randomised 
controlled trials that testing asymptomatic women reduces the 
risk of PID, and the trials at lower risk of bias show smaller 
reductions than those at higher risk of bias.18 PID can easily be 
treated if symptoms develop and the major goal behind testing 
and treating women with asymptomatic chlamydia infection is 
the potential impact of both symptomatic as well as subclinical 
and silent PID on female fertility (TFI).19 However, there is a 
paucity of evidence that widespread testing indeed will reduce 
TFI. A crucial knowledge gap is uncertainty at what moment 
in time tubal damage occurs in the natural course of infection, 
and whether treatment of asymptomatic cases can be in time to 
prevent adverse outcomes once the infection is detected. Tubal 
tissue damage might already have occurred between acquisition 
of the infection and the detection, which might partly explain 
why tested (and treated) women have higher complication rates 
compared with those not tested.20–22
Realistic estimates of the preventable fraction of adverse 
fertility outcomes are difficult to obtain as observational studies 
are fraught with bias.22 There are no controlled studies using TFI 
and ectopic pregnancy as outcome measure. The long time lapse 
between infection and planned pregnancy makes such trials very 
difficult and therefore we depend on modelling. A multiparam-
eter evidence synthesis estimated that 1000 chlamydia infections 
in women will lead to five cases of TFI and two cases of ectopic 
pregnancy.18 In an analysis of a Dutch cohort study of women 
with and without a history of chlamydia infection, we observed 
only a slight difference in time to pregnancy, and overall no 
difference in the proportion getting pregnant, suggesting that 
the effect of chlamydia control in preventing late complications 
that result in infertility might be very small.23
Other potential reproductive health complications of a chla-
mydia infection are adverse pregnancy outcomes like preterm 
birth, low birth weight and postpartum infections in mother 
and/or newborn.24 25 Although many observational studies show 
these associations, controlled studies are needed to demonstrate 
that screening and treating asymptomatic chlamydia infections 
during pregnancy can reduce these adverse outcomes. For bacte-
rial vaginosis (BV), similar associations with preterm birth and 
low birth weight have been reported consistently, but studies 
have repeatedly shown no net benefits of BV testing and treating 
of pregnant women, and the US Preventive Services Task Force 
now recommends against BV screening in pregnant persons.26
For men, complication rates of chlamydia infections—
excluding Lymfogranuloma venereum—are low, and most 
infections are asymptomatic and self- limiting. An important 
argument to test for asymptomatic chlamydia infection in MSM, 
including rectal infections, was the cofactor effect of other STIs 
in the transmission of HIV. However, the impact of this effect at 
the population level currently in high- income countries is likely 
to be small. In 2020 in the Netherlands, 93% of MSM were 
estimated to be aware of their HIV status, 95% of them was 
on treatment and 97% of those had an undetectable viral load.1 
Meanwhile, the roll- out of pre- exposure prophylaxis (PrEP) in 
HIV- negative men at risk will continue to reduce HIV incidence. 
In the current phase of the HIV epidemic in the Netherlands, 
chlamydia testing among asymptomatic MSM is unlikely to have 
major impact on numbers of averted new HIV infections. Still it 
is common practice in the Netherlands to test routinely for chla-
mydia in asymptomatic MSM up to four times a year (if they use 
PrEP) on three locations: urogenital, oral and rectal.
Potential harms from overdiagnosis and overtreatment
A number of potential harms have been reported in the past. 
A diagnosis of chlamydia can induce feelings of dirtiness and 
stigma, lead to relationship break- ups and cause anxiety about 
compromised fertility.27 Negative test results might reinforce 
unsafe sexual practices.28 A potential harm of widespread testing 
at the population level is framed in the arrested immunity 
hypothesis: early detection and treatment of infections might 
abort immune responses and render individuals more vulnerable 
for reinfection, potentially leading to more severe sequelae.29 
Although this arrested immunity remains a hypothesis, partial 
immunity and substantial reduction in susceptibility against rein-
fection was found necessary in mathematical models to explain 
observed chlamydia prevalence.30
In recent years, more attention is being paid to the health 
consequences of overdiagnosis and overtreatment. Overdiagnosis 
is defined as overdetection of a medical condition that would 
never have led to symptoms, disease or death.31 Although the 
aim is to improve health, overdiagnosis of conditions in people 
who are asymptomatic can lead to psychological stress and 
harmful interventions.32 Detecting and treating asymptomatic 
chlamydia infections might qualify for this line of reasoning. The 
vast majority of genital chlamydia infections are asymptomatic 
and self- limiting not leading to symptoms or disease. For genital 
infections, the median spontaneous clearance without treatment 
is around 1 year.17 33 Oral chlamydia infections are rare and 
asymptomatic, and spontaneous clearance rate between detec-
tion and the start of treatment is much more substantial. In a 
recent study, 50% of infections had already resolved after 9- day 
follow- up without yet having received any treatment.34 Anal 
chlamydia infections in MSM and women are mostly asympto-
matic and unrelated to reported anal sexual behaviour. Their 
natural history is poorly understood, both in terms of their path-
ogenicity as in their role in genital reinfection in women.34 35
A significant proportion of the detected extragenital infec-
tions detected by nucleic acid amplification tests appears to be 
non- viable.36 In oral chlamydia samples, percentage viability is 
reported only around in 26% and in anal samples around 60%, 
compared with 95% in genital samples. Non- viable chlamydia 
will not impact clinical outcome nor transmission.34 36 37
Testing for asymptomatic infections means that test- positive 
individuals and their, often untested and asymptomatic, part-
ners are treated with antibiotics although the majority will never 
develop either symptoms or complications. The number of 
unnecessary treated persons is much higher for chlamydia infec-
tion than for STI like HIV or syphilis. In the case of HIV, nearly 
all infected people will develop AIDS and die if left untreated. 
One- third of untreated syphilis cases will develop late complica-
tions. In contrast, for chlamydia, the risk for women to develop 
TFI is estimated less than 1%, meaning that 99% of these women 
will be treated with antibiotics unnecessarily for this indication. 
Moreover, as explained, we do not know if treatment will even 
be in time to prevent this 1%.
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Overtreatment with antibiotics in asymptomatics contributes 
to increased antimicrobial resistance (AMR). AMR is considered 
by the WHO as a major global health threat requiring strict anti-
biotic stewardship. AMR is, for now, not so much a problem for 
the C. trachomatis, which remains susceptible to standard anti-
biotic regimens. But widespread treatment with broad- spectrum 
antimicrobials can result in emergence of AMR for other STI and 
non- STI pathogens. In particular, overtreatment is of concern 
in MSM communities with high interconnectivity, and with 
frequent testing and treatment of STI, for example, during PrEP 
monitoring.38 Last but not least, antibiotic treatment affects 
oral, vaginal and rectal microbiota. A healthy microbiome is 
considered a major factor in the prevention of infections and 
reinfection.39
DISCUSSION
The expert group concluded that the changing body of evidence 
urges a re- evaluation of the benefit- to- harm ratio and the cost- 
effectiveness of widespread testing for asymptomatic chlamydia 
infections in high- income countries. The consensus of the 
expert group was that the balance between benefits and harms 
is shifting (figure 2). On the benefit side, there is a potential 
benefit in PID prevention, but high- quality empirical evidence 
for realising better fertility and pregnancy outcomes is absent. 
Meanwhile, there is evidence that the recommendations for 
widespread opportunistic testing or screening in high- income 
countries have not substantially reduced chlamydia prevalence 
in the real world. On the side of potential harms, the overdiag-
nosis of self- limiting and non- viable infections has led to overuse 
of antimicrobials, which contributes to AMR in other pathogens 
and affects microbiota.
These insights should be incorporated in future modelling 
of the impact of chlamydia interventions and the outcomes 
might differ from those of previous model- based evaluations of 
costs and benefits. They raise the question whether widespread 
opportunistic testing for asymptomatic chlamydia is good value 
for money amidst increasing healthcare costs in a restrained 
economic situation.
Considering the limited and conflicting evidence currently 
available, we do not recommend age- based screening and wide-
spread testing for chlamydia in asymptomatic persons in the 
Netherlands. Instead, we see targeted testing combined with 
effective management strategies (appropriate treatment and 
partner notification) and prevention (eg, behavioural counsel-
ling) as a way forward. This targeted strategy we define as ‘infec-
tious disease control’ and focuses on harm reduction, in contrast 
to a ‘test and treat strategy’ that aims to detect as much infec-
tions as possible (‘infection control’).4
New developments, including genetic profiling, immunoge-
netics, biomarkers and diagnostic innovations to characterise 
the infection (viability PCR/bacterial load), are expected to 
be helpful for this targeted and tailored strategy in the nearby 
future.
If scaling down widespread testing for asymptomatic chla-
mydia infections in the Netherlands is adopted, this will need 
strategic planning, co- creation with communities and careful 
monitoring, with an explicit agenda for research and evaluation 
as this approach deviates from earlier policies. In recent decades, 
health authorities have promoted just the opposite: widespread 
chlamydia testing has been incorporated in national guidelines, 
and public campaigns in the media have informed the public that 
chlamydia is the number one STI.
To change existing perceptions and practices, even with newly 
emerging and growing evidence, is not an easy task. Doing less 
rather than more is even more difficult to ‘sell’. Moreover, there 
are strong lobby and profit- oriented interests that benefit from 
the promotion of testing, including those of diagnostic compa-
nies and for- profit commercial self- test or self- sample internet 
services.
Next steps
A multifaceted stepped approach was developed during the 
workshop in how to proceed.
Development of a new roadmap
First of all, discussion should be promoted in guideline commit-
tees and in the professional community about the current scien-
tific state of the art in benefits and harms of widespread testing 
of asymptomatic individuals. The viewpoint raised during this 
meeting suggests a paradigm shift and deviates from the ‘test and 
treat’ approach. International collaboration needs to be sought 
to reappraise the guidance on appropriate care and prevention in 
national and international guidelines. An update of the Cochrane 
review on screening for genital chlamydia18 as well as updated 
guidance on chlamydia control interventions from international 
organisations such as the European Centre for Disease Preven-
tion and Control and WHO would be helpful.
Creation of an evidence-based narrative and description of 
knowledge gaps
Our viewpoint implies a different perception of a chlamydia 
infection, to be considered more as a common infection with 
uncommon severe complications than its portrayal as a silent 
killer of fertility. It raises the question if—and at what costs—
every asymptomatic infection must be detected and must be 
treated. If chlamydia is considered as akin to Mycoplasma geni-
talium, the current approach to M. genitalium, that is—do not 
test unless symptomatic because widespread testing does more 
harm than good—needs to be critically reviewed also as a possible 
strategy for chlamydia. There are still critical knowledge gaps on 
the natural history of chlamydia infection. The consensus of the 
expert group was that the focus of research should be on deter-
minants of complications rather than on determinants of infec-
tion. There is still a lack of controlled intervention studies that 
use clinical disease outcomes (in particular adverse fertility and 
Figure 2 Chlamydia appraisal: shifting balance between benefits and 
harms.
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pregnancy outcomes). Personalised and tailored clinical manage-
ment and public health research can help to identify persons and 
populations who will benefit most without compromising the 
health of others.
Involve stakeholders and do not compromise sexual health
Care should be taken not to endanger the progress made in 
putting sexual health on the agenda, integrating prevention of 
STI, contraceptive services and positive attention for sexuality. 
Involvement of communities of youth, MSM and other stake-
holders is therefore crucial in exploring future testing policies. 
Consideration should also be given to include diagnostic compa-
nies even though their market objectives are different. As a main 
reason for encounters with a sexual health professional for many 
individuals might be a request for a chlamydia or other STI 
tests, additional measures are warranted to prevent any negative 
impact on sexual healthcare seeking behaviour. Exploration of a 
bigger role for primary prevention is recommended.
Communicate and evaluate
Communicating wisely both in the professional field, as well 
as in the public domain, is imperative to facilitate shared deci-
sion taking and not to compromise faith in health authorities if 
different updated perspectives and guidelines are presented that 
deviate from earlier policies and practices. Given the areas of 
uncertainty surrounding a policy shift, monitoring and evalua-
tion of any change of practices that take place will be essential. 
Surveillance systems should be in place to monitor any (adverse) 
consequences, including PID surveillance. A shift in chlamydia 
policy should not compromise testing of symptomatic persons, 
nor endanger early detection and treatment of other STIs like 
syphilis, gonorrhoea, HIV and hepatitis.
CONCLUSION
The expert group’s consensus and interpretation of evidence 
was that chlamydia control is at crossroads. Opportunities for 
widespread testing are increasing, but the benefit–harm ratio 
of testing persons without symptoms is changing. Future strat-
egies should shift their focus from infection control, promoting 
widespread testing, towards disease management, limiting and 
targeting testing, aiming at harm reduction.
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